Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.295 CAD | 0.00% | 0.00% | -68.28% |
Apr. 24 | Antibe Therapeutics Inc. Announces Board Resignations | CI |
Apr. 19 | Antibe Therapeutics Seeks Extension of Stay of Proceedings | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 15.64M 11.44M |
---|---|---|---|---|---|
Net income 2024 * | -19M -13.9M | Net income 2025 * | -15M -10.97M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-1.02
x | Employees | 11 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.06% |
Current month | -34.44% | ||
1 month | -31.40% | ||
3 months | -67.58% | ||
6 months | -50.83% | ||
Current year | -68.28% |
Managers | Title | Age | Since |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 15-11-30 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 50 | 20-11-23 | |
Amal Khouri
BRD | Director/Board Member | - | 18-03-18 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.28% | 11.4M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.78% | 22.2B | |
-16.53% | 21.23B | |
-9.14% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- ATE Stock